Covalently conjugated VEGF-fibrin matrices for endothelialization

被引:273
作者
Zisch, AH
Schenk, U
Schense, JC
Sakiyama-Elbert, SE
Hubbell, JA
机构
[1] Swiss Fed Inst Technol, Dept Mat, CH-8044 Zurich, Switzerland
[2] Swiss Fed Inst Technol, Inst Biomed Engn, CH-8044 Zurich, Switzerland
[3] Univ Zurich, CH-8044 Zurich, Switzerland
关键词
D O I
10.1016/S0168-3659(01)00266-8
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
Vascular endothelial growth factor (VEGF) is a key factor in endothelial cell biology and blood vessel formation and a candidate therapeutic for the stimulation of angiogenesis-dependent tissue regeneration. The objective of this study was to confer the angiogenic activity of VEGF(121) upon the biomaterial fibrin, a natural substrate for endothelial cell growth and clinically accepted as 'fibrin glue'. To achieve this, we engineered fibrin-based hydrogels that were covalently modified with VEGF(121). Our laboratory has recently developed novel methodology that allows the covalent incorporation of exogenous bioactive peptides by the transglutominase activity of factor XIIIa into fibrin during cogulation. Here, this ability of factor XIIIa to crosslink additional proteins within fibrin was employed to covalently incorporate VEGF(121). By recombinant DNA methodology, a mutant VEGF(121) variant, alpha (2)-PI1-8-VEGF(121), which contains an additional factor XIIIa substrate sequence NQEQVSPL at the aminoterminus, was expressed in E. coli. In soluble form, the mutant protein fully retained its mitogenic activity for endothelial cells. Using I-125-labeled alpha (2)-PI1-8-VEGF(121), its covalent incorporation and the efficiency of incorporation into fibrin was demonstrated and characterized. The immobilized, fibrin-conjugated VEGF(121) protein remained an active and very efficient mitogen for human endothelial cells grown on two-dimensional VEGF(121)-modified fibrin surfaces, and the incorporation of increasing amounts of alpha (2)-PI1-8-VEGF(121) resulted in dose-dependent enhancement of endothelial cell growth. The VEGF-modified fibrin matrices can be formed as injectable gels in a single-step reaction under physiological conditions in vivo. When used as a ingrowth matrix, such VEGF incorporating materials could be useful in a variety of clinical situations that require an angiogenic response into an ischemic region or inplant. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:101 / 113
页数:13
相关论文
共 41 条
[1]
LOCAL-DELIVERY OF VASCULAR ENDOTHELIAL GROWTH-FACTOR ACCELERATES REENDOTHELIALIZATION AND ATTENUATES INTIMAL HYPERPLASIA IN BALLOON-INJURED RAT CAROTID-ARTERY [J].
ASAHARA, T ;
BAUTERS, C ;
PASTORE, C ;
KEARNEY, M ;
ROSSOW, S ;
BUNTING, S ;
FERRARA, N ;
SYMES, JF ;
ISNER, JM .
CIRCULATION, 1995, 91 (11) :2793-2801
[2]
ASAHARA T, 1996, CIRCULATION, V94, P2892
[3]
ANGIOGENIC-INDUCED ENHANCEMENT OF COLLATERAL BLOOD-FLOW TO ISCHEMIC MYOCARDIUM BY VASCULAR ENDOTHELIAL GROWTH-FACTOR IN DOGS [J].
BANAI, S ;
JAKLITSCH, MT ;
SHOU, M ;
LAZAROUS, DF ;
SCHEINOWITZ, M ;
BIRO, S ;
EPSTEIN, SE ;
UNGER, EF .
CIRCULATION, 1994, 89 (05) :2183-2189
[4]
Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [J].
Baumgartner, I ;
Pieczek, A ;
Manor, O ;
Blair, R ;
Kearney, M ;
Walsh, K ;
Isner, JM .
CIRCULATION, 1998, 97 (12) :1114-1123
[5]
Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor [J].
Birkenhager, R ;
Schneppe, B ;
Rockl, W ;
Wilting, J ;
Weich, HA ;
McCarthy, JEG .
BIOCHEMICAL JOURNAL, 1996, 316 :703-707
[6]
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele [J].
Carmeliet, P ;
Ferreira, V ;
Breier, G ;
Pollefeyt, S ;
Kieckens, L ;
Gertsenstein, M ;
Fahrig, M ;
Vandenhoeck, A ;
Harpal, K ;
Eberhardt, C ;
Declercq, C ;
Pawling, J ;
Moons, L ;
Collen, D ;
Risau, W ;
Nagy, A .
NATURE, 1996, 380 (6573) :435-439
[7]
CLOWES AW, 1986, AM J PATHOL, V123, P220
[8]
In vitro endothelialization of expanded polytetrafluoroethylene grafts: A clinical case report after 41 months of implantation [J].
Deutsch, M ;
Meinhart, J ;
Vesely, M ;
Fischlein, T ;
Groscurth, P ;
vonOppell, U ;
Zilla, P .
JOURNAL OF VASCULAR SURGERY, 1997, 25 (04) :757-763
[9]
EXPERIMENTAL USE OF A MODIFIED FIBRIN GLUE TO INDUCE SITE-DIRECTED ANGIOGENESIS FROM THE AORTA TO THE HEART [J].
FASOL, R ;
SCHUMACHER, B ;
SCHLAUDRAFF, K ;
HAUENSTEIN, KH ;
SEITELBERGER, R .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1994, 107 (06) :1432-1439
[10]
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442